Table 1.
Summary of the seven colorectal cancer genome-wide association studies.
| Series | Study setting | Study centre | Genotyping platform | No. cases | No. controls |
|---|---|---|---|---|---|
| CCFR1 | Colon Cancer Family Registry | University of Southern California | Illumina 1M, 1M Duo | 1290 | 1055 |
| CCFR2 | Colon Cancer Family Registry | University of Southern California | Illumina 1M, Omni express | 796 | 2236 |
| COIN | COIN trial: Multicentre study of cetuximab and other therapies in metastatic CRC. Controls were unselected blood donors | Cardiff University | Affymetrix Axiom | 2244 | 2162 |
| FINLAND | Finnish Colorectal Cancer Predisposition Study | Helsinki University | Illumina 610K/Illumina HumanOmni2.5M | 1172 | 8266 |
| UK1 | CORGI (colorectal Tumour Gene Identification Consortium) | Oxford University | Illumina Hap550 | 940 | 965 |
| Scotland1 | COGS (Colorectal Cancer Susceptibility Study) | Edinburgh University | Illumina Hap300/240S | 1012 | 1012 |
| VQ58 | Cases: VICTOR, post-treatment stages of a phase III, randomised trial of rofecoxib (VIOXX) in patients after potentially curative therapy. QUASAR2, multi-centre study of capecitabine ± bevacizumab as adjuvant treatment. 1958 Birth cohort controls | Oxford University | Illumina Hap300/370, Illumina 1M | 1800 | 2690 |